Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX Stock Outperforms Industry Image Source: Zacks Investment Research The ...

In December 2023, Vertex announced encouraging data from a phase II study of VX-548 for painful diabetic peripheral neuropathy (DPN), a form of peripheral neuropathic pain caused by damage to nerves.

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the shares.The firm had previously indicated that shares ...

Vertex AI Search for healthcare's new ... where nearly 90% of healthcare data is in image form – such as x-rays, scans, or photos. To give healthcare professionals a comprehensive understanding ...